Novel Technologies

Novel Technologies

We strive toward enrolling 2,000 confirmed hemophilia carriers in the MLOF Research Repository.Read More
Like hepatitis C, hepatitis B is a viral infection in the liver. The infection can be acute or chronic, in...Read More
The most common inherited bleeding disorder, von Willebrand disease (VWD) has also been one of the most difficult to diagnose....Read More
Two subcutaneous therapies are currently being investigated.Read More
MLOF is open to all people with hemophilia A and B.Read More
More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.Read More
The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.Read More
Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.Read More
An update on FVII gene therapy and more.Read More
Telemedicine can bridge the distance between doctor and patients.Read More
Updates on Daklinza, Technivie, and the ACE910 trialRead More
Five pilot sites have been approved and first patients enrolledRead More
Chat Icon
Need Info? Ask NHF!
Contact HANDI, NHF's resource center for additional information on bleeding disorders.